177 related articles for article (PubMed ID: 37324490)
1. Profile and potential role of novel metabolite biomarkers, especially indoleacrylic acid, in pathogenesis of neuromyelitis optica spectrum disorders.
Bian J; Sun J; Chang H; Wei Y; Cong H; Yao M; Xiao F; Wang H; Zhao Y; Liu J; Zhang X; Yin L
Front Pharmacol; 2023; 14():1166085. PubMed ID: 37324490
[No Abstract] [Full Text] [Related]
2. Decreased kynurenine in cerebrospinal fluid and potential role in neuromyelitis optica spectrum disorder.
Peng F; She H; Wang Y; Xu L; Shan Y; Chang Y; Zhong X; Li R; Qiu W; Shu Y; Tan S
J Neurochem; 2023 Apr; 165(2):259-267. PubMed ID: 36718502
[TBL] [Abstract][Full Text] [Related]
3. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
[TBL] [Abstract][Full Text] [Related]
4. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
[TBL] [Abstract][Full Text] [Related]
5. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
6. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
7. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.
Kim S; Lee JJ; Park JS; Kang M; Seok HY
Neurol Sci; 2024 Mar; 45(3):1255-1261. PubMed ID: 38141119
[TBL] [Abstract][Full Text] [Related]
9. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
[TBL] [Abstract][Full Text] [Related]
10. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
11. Decreased serum tryptophan levels in patients with MOGAD:a cross-sectional survey.
Chang H; Sun J; Ma J; Zhao Y; Guo T; Wei Y; Cong H; Yin L; Zhang X; Wang H
Clin Chim Acta; 2024 May; 558():119669. PubMed ID: 38599541
[TBL] [Abstract][Full Text] [Related]
12. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
13. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
[TBL] [Abstract][Full Text] [Related]
14. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.
Du L; Chang H; Xu W; Zhang X; Yin L
Mult Scler Relat Disord; 2021 Jul; 52():102940. PubMed ID: 33930716
[TBL] [Abstract][Full Text] [Related]
15. Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders.
Shi Z; Du Q; Wang X; Wang J; Chen H; Lang Y; Kong L; Luo W; Yang M; Zhou H
Front Immunol; 2022; 13():1027158. PubMed ID: 36439094
[TBL] [Abstract][Full Text] [Related]
16. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity.
Peng Y; Chen J; Dai Y; Jiang Y; Qiu W; Gu Y; Wang H
Mult Scler Relat Disord; 2020 Apr; 39():101888. PubMed ID: 31869599
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
Kim H; Lee EJ; Kim S; Choi LK; Kim HJ; Kim HW; Chung K; Seo D; Moon S; Kim KK; Lim YM
Mult Scler; 2022 Apr; 28(4):512-521. PubMed ID: 34212756
[TBL] [Abstract][Full Text] [Related]
19. Increased cerebrospinal fluid YKL-40 levels are associated with disease severity of neuromyelitis optica spectrum disorders.
Qi Y; Chou LS; Zhang LJ; Liu MQ; Yi M; Zhang QX; Wang J; Li T; Zhang DQ; Yang L
Mult Scler Relat Disord; 2020 Oct; 45():102395. PubMed ID: 32679524
[TBL] [Abstract][Full Text] [Related]
20. Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack.
Cha E; Lee KM; Park KD; Park KS; Lee KW; Kim SM; Lee J
PLoS One; 2016; 11(12):e0167819. PubMed ID: 27942009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
